Japanese firms link up to develop HCC (hepatocellular carcinoma) test kit:
This article was originally published in Clinica
Three Tokyo firms - Sanko Junyaku, Eisai and Fujirebio - have signed a joint research agreement to develop a test kit for hepatocellular carcinoma (HCC), the fourth leading cause of malignant-tumour related death in Japan. The kit will test for DCP (des-gamma-carboxy prothrombin), a marker for HCC. It will be used exclusively with Fujirebio's Lumipulse chemiluminescent enzyme immunoassay system. Fujirebio will manufacture the product for distribution by Sanko Junyaku and sales partner Eisai.